Joseph Douglas Lyon - Dec 1, 2023 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Chief Accounting Officer
Signature
/s/ Joseph Douglas Lyon
Stock symbol
CORT
Transactions as of
Dec 1, 2023
Transactions value $
-$61,304
Form type
4
Date filed
12/5/2023, 06:59 PM
Previous filing
Nov 3, 2023
Next filing
Feb 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise $29.1K +2.57K +43.87% $11.35 8.42K Dec 1, 2023 Direct F1
transaction CORT Common Stock Sale -$66.8K -2.57K -30.49% $26.00 5.85K Dec 1, 2023 Direct F1, F2
transaction CORT Common Stock Options Exercise $27.6K +2.43K +41.54% $11.35 8.29K Dec 4, 2023 Direct F1
transaction CORT Common Stock Sale -$63.2K -2.43K -29.35% $26.00 5.85K Dec 4, 2023 Direct F1, F2
transaction CORT Common Stock Award $11.9K +460 +7.86% $25.97 6.31K Dec 1, 2023 Direct F1, F3, F4
transaction CORT Common Stock Award $0 +460 +7.29% $0.00 6.77K Dec 1, 2023 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -5K -10.17% $0.00 44.2K Dec 1, 2023 Common Stock 5K $11.35 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2 The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
F3 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on December 1, 2023.
F4 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F5 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F6 Fully exercisable.